Newsroom | Arrowhead Pharmaceuticals
1 day ago · Stay up to date on Arrowhead Pharmaceutical's latest news, stories, and events. Read about recent studies on potential treatments, healthcare conferences, and more!
Arrowhead Pharmaceuticals Announces Global License and …
1 day ago · Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT). Upon closing, Arrowhead will receive $825 million, consisting of $500 million cash and $325 million as an equity investment priced at a 35% premium.
Arrowhead Pharmaceuticals Announces Global License and …
1 day ago · PASADENA, Calif., November 26, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT). Upon ...
Arrowhead Pharmaceuticals Nabs Massive Sarepta Licensing …
1 day ago · Arrowhead shares rocketed 12% to close at 21.05 and ARWR stock leapfrogged its 50-day line, according to MarketSurge. Sarepta stock jumped too, 13.8% to 130.50, putting it above its 50-day moving ...
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
20 hours ago · – Conference Call and Webcast Today, November 26, 2024, at 4:30 p.m. ET PASADENA, Calif.–(BUSINESS WIRE)–Nov. 26, 2024– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, at 4:30 p.m. ET to discuss the results. […]
Sarepta, Arrowhead Pharmaceuticals partner to advance RNA …
1 day ago · Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based drugs to treat rare diseases in the muscle, nervous system ...
Arrowhead Pharmaceuticals Submits New Drug Application to …
Nov 18, 2024 · PASADENA, Calif.--(BUSINESS WIRE)--Nov. 18, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a …
Arrowhead Pharmaceuticals Submits FDA Application for …
5 days ago · 3. Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran. News release. Arrowhead Pharmaceuticals. November 18, 2024.
Arrowhead Pharmaceuticals Eyes Future Growth with Strategic …
10 hours ago · Arrowhead Pharmaceuticals, Inc. ( (ARWR) ) has released its Q4 earnings. Here is a breakdown of the information Arrowhead Pharmaceuticals, Inc. ...
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
20 hours ago · PASADENA, Calif., November 26, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a ...